Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease”

Huang, Chung-Feng; Yeh, Ming-Lun; Dai, Chia-Yen; Huang, Jee-Fu; Chuang, Wan-Long; Yu, Ming-Lung

doi:10.1016/j.cgh.2024.04.023

Clinical Gastroenterology and Hepatology

2024

DOI: 10.1016/j.cgh.2024.04.023

|View full text |Cite

Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease”

Chung-Feng Huang,

Ming-Lun Yeh,

Chia-Yen Dai

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Sanal,

Gish,

Méndez-Sánchez

et al. 2024

Metab Target Organ Damage

View full text Add to dashboard Cite

The recent shift from “non-alcoholic fatty liver disease” (NAFLD) and “metabolic associated fatty liver disease” (MAFLD) to “metabolic dysfunction-associated steatotic liver disease” (MASLD) has raised questions about its scientific basis and impact on patient understanding. This renaming may create confusion rather than clarity. A collaborative approach involving healthcare professionals, researchers, and patients to establish terminology that balances scientific accuracy with accessibility is needed. Effective disease naming should be accurate, unique, consistent, objective, and accessible - qualities essential for clear communication in healthcare. Disease name is more than scientific correctness because naming conventions for public use, especially anything related to health, must be a matter of convenience, ethics, and cultural and social acceptance. Education and straightforward communication should take precedence over renaming, helping patients and healthcare providers fully understand the complexities and implications of liver disease for treatment. After all, from a scientific and public health perspective, MAFLD has clear advantages over MASLD.

show abstract

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Sanal,

Gish,

Méndez-Sánchez

et al. 2024

Metab Target Organ Damage

View full text Add to dashboard Cite

show abstract

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Huang,

Dai,

Lin

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

Background/AimsSteatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution. MethodsWe enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure. ResultsThere were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1C (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m 2 vs. 24.7 kg/m 2 , P<0.001) decreased, whereas HDL-C (49.1 mg/dL vs. 51.9 mg/dL, P<0.001) and triglycerides (102.8 mg/dL vs. 111.9 mg/dL, P<0.001) increased significantly. The proportion of patients with SLD was 37.5% after HCV eradication, which did not change significantly compared with the pretreatment status. The percentage of the patients who had post-treatment MASLD was 34.8%, which did not differ significantly from the pretreatment status (P=0.17). Body mass index (BMI) (odds ratio [OR]/95% confidence intervals [

show abstract

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Huang,

Awad,

Gal-Tanamy

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease”

Cited by 3 publications

References 9 publications

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Contact Info

Product

Resources

About